Is C-reactive protein an additional, surrogate end-point for statin treatment?

Abstract

simple approach to lower urate levels with allopurinol, large, simple and relatively affordable clinical trials are feasible. These trials can be facilitated by funding from governments or by ‘factoring’ this in with other interventional trials evaluating new pharmacological agents. In conclusion, the findings by Wong et al. are provocative enough to be… (More)

Topics

Cite this paper

@article{Kluft2002IsCP, title={Is C-reactive protein an additional, surrogate end-point for statin treatment?}, author={Cornelius Kluft}, journal={European heart journal}, year={2002}, volume={23 10}, pages={761-4} }